ABOS — Acumen Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1576885 ·
Last close
$0.23
Market Cap
$16.64M
52W High
$3.60
52W Low
$0.19
ADV30
5,055,869
Next earnings
2026-10-26
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -25,813,000 | -25,369,000 | 85,565,000 | 53,075,000 | 50,955,000 |
| Jun 2026 | 0 | — | -32,556,000 | -32,718,000 | 116,007,000 | 59,443,000 | 58,744,000 |
| Mar 2026 | 0 | — | -21,149,000 | -20,737,000 | 133,629,000 | 51,796,000 | 46,153,000 |
| Dec 2025 | 0 | — | -25,199,000 | -25,138,000 | 122,833,000 | 53,989,000 | 52,403,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-87,952,000
Investing CF
$63,693,000
Financing CF
$30,501,000
CapEx
$-88,000
Dividends Paid
—
Buybacks
$-149,000
EPS Diluted TTM
$-1.57
As of
2026-11-01
Balance + Analyst (yfinance extras)
Retained Earnings
$-525,286,000
Inventory
—
Receivables
$1,747,000
ST Investments
$25,529,000
EBIT TTM
$-99,713,000
Pretax Income TTM
$-103,962,000
Interest Exp TTM
$4,249,000
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -123,832,000 | -121,335,000 | 122,833,000 | 52,403,000 | 70,430,000 | -115,538,000 |
| Dec 2024 | 0 | -114,017,000 | -102,329,000 | 238,992,000 | 57,176,000 | 181,816,000 | -86,215,000 |
| Dec 2023 | 0 | -61,138,000 | -52,371,000 | 310,125,000 | 43,152,000 | 266,973,000 | -43,064,000 |
| Dec 2022 | 0 | -45,237,000 | -42,856,000 | 196,587,000 | 7,812,000 | 188,775,000 | -35,153,000 |
TTM Snapshot
Revenues TTM
$5,136,000
NetIncome TTM
$-105,044,000
OpCashFlow TTM
—
Assets (Latest)
$116,007,000
Forward EPS
$-0.49
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BSEM | BioStem Technologies, Inc. | $17.93M | $0.94 | — |
| CKDXF | Opthea Ltd | $14.64M | $0.01 | — |
| ESLA | Estrella Immunopharma, Inc. | $14.42M | $0.33 | — |
| PLUR | Pluri Inc. | $14.09M | $0.98 | — |
| PASG | Passage BIO, Inc. | $13.58M | $4.22 | — |
News headlines (Yahoo Finance, 1h cache)
Alzheimer's families just lost one of their biggest hopes
2026-11-10 00:37 · Yahoo
Acumen Pharmaceuticals: 3 Key Takeaways for Long-Term Investors
2026-11-05 02:08 · Yahoo
Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint
2026-10-30 11:00 · Yahoo
Acumen Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
2026-10-26 16:42 · Yahoo
Acumen Pharmaceuticals (ABOS) Q3 2026 Earnings Call Transcript
2026-10-26 16:12 · Yahoo
Acumen Pharmaceuticals Reports Smaller Q3 Loss, Shares Rise as Phase 2 Alzheimer’s Data Approach
2026-10-26 14:09 · Yahoo
Acumen Pharmaceuticals Q3 Earnings Call Highlights
2026-10-26 14:02 · Yahoo
Acumen Pharmaceuticals beats Q3 estimates, shares jump 6%
2026-10-26 12:07 · Yahoo
Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights
2026-10-26 11:00 · Yahoo
Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Dis
2026-10-22 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.